ArticleEuropean journal of clinical pharmacology2006
Effect of clinical trial publicity on HRT prescribing in Ireland.
Article in European journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The 2017 Women's Health Initiative study and use of hormone therapy: an emulated repeated cross-sectional study.BMC public health · 2024Article
- Changes in Drug Utilization After Publication of Clinical Trials and Drug-Related Scandals in Japan: An Interrupted Time Series Analysis, 2005-2017.Journal of epidemiology · 2021Article
- Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.European journal of cancer (Oxford, England : 1990) · 2017Article
- Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data.European journal of clinical pharmacology · 2017Article
- Exposure to oral bisphosphonates and risk of cancer.International journal of cancer · 2012Article
- Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization.Menopause (New York, N.Y.) · 2011Article
- Article
- Long-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribing.Journal of women's health (2002) · 2010Article
- Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2008Article
- Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004.The Journal of rheumatology · 2008Article
- Do Finnish women using hormone replacement therapy need more information about risks.Pharmacy world & science : PWS · 2007Article
- Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003.BMC women's health · 2007Article
- What therapies have replaced rofecoxib in Ireland?British journal of clinical pharmacology · 2007Article
- Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.European journal of clinical pharmacology · 2007Article
- Impact of high dose statin trials on hospital prescribers.European journal of clinical pharmacology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of publicity surrounding the Women's Health Initiative (WHI) and Million Women (MW) studies on prescribing of all hormone replacement therapy (HRT) preparations and bisphosphonates in Ireland.
methodsThe General Medical Services (GMS) prescription database was used to identify the study population. Prescriptions were identified for HRT and bisphosphonate preparations [using WHO Anatomical Therapeutic Chemical (ATC) classification codes] in female patients aged 45-69 years in Ireland during a 4-year study period (January 2001-December 2004). Prescription rates were calculated monthly. Prevalence and incidence of HRT use was examined.
resultsThere was a significant reduction in prevalence for all HRT preparations following the WHI trial (test for change in trend p<0.0001), which persisted after the MW study. The incidence of combined oestrogen/progestogen HRT declined after the WHI trial (test for change in trend p=0.004). Bisphosphonate prescribing showed a significant increase throughout the study period (p<0.0001).
conclusionThe findings suggest that coverage surrounding the publication of clinical trials appears to have had a negative impact on the rate of HRT prescribing. The findings regarding the coincident increase in use of bisphosphonates may suggest that prescribers and users were less likely to regard HRT as an appropriate therapy in the management of osteoporosis for some time before guidance was issued by the regulatory authorities.
Indexed as
Identifiers
16432715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.